Stereotactic Body Radiation Therapy for Colorectal Cancer Liver Metastases; Early Results

BURKOŇ, Petr, Pavel ŠLAMPA, Tomáš KAZDA, Marek SLÁVIK, T. PROCHÁZKA and M. VRZAL. Stereotactic Body Radiation Therapy for Colorectal Cancer Liver Metastases; Early Results. Klinická onkologie. Praha: Česká lékařská společnost J.E.Purkyně, 2012, vol. 25, SUPPL. 2, p. 2S93-2S97, 5 pp. ISSN 0862-495X.

Basic information

• Original name: Stereotactic Body Radiation Therapy for Colorectal Cancer Liver Metastases; Early Results
• Name in Czech: Stereotaktická radioterapie jaterních metastáz kolorektálního karcinomu; časné výsledky
• Authors: BURKOŇ, Petr (203 Czech Republic, guarantor, belonging to the institution), Pavel ŠLAMPA (203 Czech Republic, belonging to the institution), Tomáš KAZDA (203 Czech Republic, belonging to the institution), Marek SLÁVIK (703 Slovakia, belonging to the institution), T. PROCHÁZKA (203 Czech Republic) and M. VRZAL (203 Czech Republic).
• Edition: Klinická onkologie, Praha, Česká lékařská společnost J.E.Purkyně, 2012, 0862-495X.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: Czech Republic
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• RIV identification code: RIV/00216224:14110/12:00063928
• Organization unit: Faculty of Medicine
• Keywords (in Czech): kolorektální karcinom – metastázy – játra – radioterapie – extrakraniální stereotaktická terapie
• Keywords in English: colorectal neoplasms – neoplasm metastasis – liver – radiation therapy – stereotactic body radiotherapy
• Tags: Reviewed

Abstract

for treatment of colorectal cancer liver metastases. Materials and Methods: From September 2009 to December 2011, 11 patients with 15 inoperable liver metastases of colorectal cancer were treated by SBRT using Varian Clinac iX linear accelerator. We treated 6 men and 5 women of age from 51 to 81 years (median 68). SBRT doses ranged from 40 to 56 Gy (median 54 Gy) and were administered in 3 to 8 fractions. Results: Local control rates at 2, 4, 6, 9 and 12 months after completion of SBRT were 100%, 91%, 91%, 67% and 50%, respectively. Disease progression-free survival rates at 2, 4, 6, 9 and 12 months were 82%, 82%, 64%, 50% and 50%, respectively. Median follow-up was 15 months. No severe side effects were attributed to the therapy. Conclusion: Our study assessed the feasibility of SBRT in selected group of patients with 1 to 3 colorectal cancer liver metastases with no other treatment option. We achieved excellent local control and very moderate acute and late side effects. Distant metastases were the most common recurrence form after SBRT. SBRT demonstrated excellent local control and resulted in occasional long-term survivors without any serious side effects of therapy.